View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 10, 2020updated 22 Nov 2021 12:41pm

Moderna teams up with ROVI to provide Covid-19 vaccine outside US

US-based biotechnology firm Moderna has partnered with European pharmaceutical company Laboratorios Farmacéuticos Rovi (ROVI) for finish-fill manufacturing of its Covid-19 vaccine candidate, mRNA-1273.

US-based biotechnology firm Moderna has partnered with European pharmaceutical company Laboratorios Farmacéuticos Rovi (ROVI) for finish-fill manufacturing of its Covid-19 vaccine candidate, mRNA-1273.

As part of the deal, ROVI will be responsible for large-scale, commercial fill-finish manufacturing of the vaccine product at its facility in Madrid, Spain.

The company will provide vial filling and packaging capacity via a new production line and equipment to carry out compounding and filling, as well as automatic visual inspection and labelling.

This is expected to support the manufacture of millions of doses of Moderna’s mRNA-1273 for supply primarily in markets outside of the US, from early next year.

ROVI plans to hire additional staff to support manufacturing activities and production.

ROVI CEO Juan López-Belmonte said: “Our proven experience and capabilities as a toll manufacturer of injectables has allowed us to reach this agreement, which would help strengthen our manufacturing area and would, in all probability, provide us with a significant growth opportunity in the area.”

MRNA-1273 is an mRNA vaccine product that encodes for a prefusion stabilised form of the Spike (S) protein, selected by the company in partnership with Vaccine Research Center (VRC) at the US National Institute of Allergy and Infectious Diseases (NIAID).

The vaccine candidate received fast-track designation from the US Food and Drug Administration (FDA) in May. It is currently in Phase II clinical trial, with plans to launch a Phase III trial this month.

Moderna chief technology operations and quality officer Juan Andres said: “We are pleased to partner with ROVI to potentially supply hundreds of millions of doses of finished mRNA-1273, once approved, and help address the need for a vaccine against Covid-19 around the world.

“ROVI’s experience as a global manufacturer of drug product and expertise in fill-finish will be an important partnership for us to establish dedicated supply chains that can meet the needs of different countries and regions.”

Last month, Moderna collaborated with manufacturing solutions provider Catalent for large-scale, commercial fill-finish manufacturing of mRNA-1273 in the US.

In May, Moderna signed a ten-year agreement with Lonza for large-scale manufacture of its Covid-19 vaccine candidate and other products in the future.

Related Companies

Free Report

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy